Spike S1 RBD (B.1.351, Beta Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit

Catalog #
78152
$995 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Spike S1 RBD-B.1.351 (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the RBD region of the B.1.351 Variant of the SARS-CoV-2 Spike S1 protein. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike S1 RBD-B.1.351 is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike S1 RBD-B.1.351 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce color, which can then be measured using a UV/Vis spectrophotometer microplate reader.

Assay Principle

Assay Principle

 

Synonyms
Sars-cov-2 B.1.351, 501Y.V2 kit, South African variant inhibitor screening, colorimetric, Spike RBD kit, B.1.351 inhibitor kit
Product Info
Storage and Usage
Citations
Assay Kit Format
Colorimetric
Species
SARS-CoV-2
Supplied As
This kit comes in a convenient 96-well format, with purified Spike RBD-B.1.351 (SARS-CoV-2) and ACE2-Biotin proteins, streptavidin-HRP, colorimetric HRP substrate, and assay buffer for 100 binding reactions.
Materials Required But Not Supplied

PBS (Phosphate buffered saline)
1N HCl (aqueous)
Rotating or rocker platform
UV/Vis spectrophotometer microplate reader capable of reading absorbance at 450 nm

Format

Catalog 

Name

Amount

Storage

100978

SARS RBD-B.1.351

5 µg

-80°C

100665

ACE2, His-Avi-Tag, Biotin-labeled HiP™

5 µg

-80°C

79742

Streptavidin-HRP

15 µl

+4°C

79311

3x Immuno Buffer 1

50 ml

-20°C

79728

Blocking Buffer 2

50 ml

+4°C

 

Colorimetric HRP substrate

10 ml

+4°C

 

Transparent 96-well microplate

1

Room Temp

 

Background

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 offer promising protection against the viral infection.


A variant strain of SARS-COV-2, identified as B.1.351, was first identified in the fall of 2020 in the Republic of South Africa. This South African variant, also known as 501Y.V2, has many mutations which may lead to higher transmissibility and infectivity. In particular, the B.1.351 variant contains three mutations within the RBD region of the Spike S1 protein: K417N, E484K, and N501Y. Investigating the effect of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.

References

Wang P. et al., 2021 bioRxiv 2021.01.25.428137.  

Shen X., et al., 2021 bioRxiv. 2021.01.27.428516.

Hoffman M. et al., 2020 Cell 181:1-10.